Tag: Biotech and Pharmaceuticals
-
Two Indian nationals charged with smuggling counterfeit Ozempic from China: DOJ
The criminal indictment in Florida comes as the use of GLP-1 drugs such as Novo’s Ozempic for weight loss has hit new highs among U.S. adults.
-
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.
-
Novo’s new strategy hinges on something it can’t manufacture: investor trust
Novo has now reached the point where it can broaden its ambitions again, CEO Mike Doustdar told CNBC, but investors remain unconvinced.
-
Trump administration removes around 760,000 Obamacare enrollments, alleging fraud
Vice President JD Vance’s White House Task Force to Eliminate Fraud estimates the action will save roughly $2.2 billion in taxpayer-funded subsidies.
-
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
They’re the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.
-
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
-
Novo Nordisk rebrands to ‘Novo,’ unveils corporate changes as it fights for obesity market share
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
-
Meet Ottava, J&J’s surgical robot leading the healthcare giant into a lucrative new market
J&J is confident that Ottava, it’s new robotic surgical system can compete in the robotic surgery market
-
‘Patients pay the tariff’: Swiss pharma CEO warns of Trump’s generic drug tariff threat
Sandoz CEO Richard Saynor warns steep U.S. tariffs on imported generic drugs could force manufacturers to raise prices or cut supply.
-
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca’s peak annual sales forecast of more than $5 billion.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
